Observational Study of Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange Therapy
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Thrombin clotting time
研究概览
简要总结
Plasma exchange is a frequently used therapy in many antibody-mediated disorders, such as humoral rejection after kidney transplantation. Treatment frequency is adjusted to daily measured fibrinogen blood levels to prevent bleeding complications. However, data about the correlation of fibrinogen blood levels and function of the coagulation system during plasma exchange therapy is scarce. In the present study we examine blood fibrinogen levels and coagulation factors as well as thrombin clotting time in patients under plasma exchange therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •plasma exchange therapy due to humoral rejection after kidney transplantation
排除标准
- •hereditary coagulopathy
- •chronic liver disease (Child C)
- •therapeutic anticoagulation
- •malnutrition (BMI<17.5)
结局指标
主要结局
Thrombin clotting time
时间窗: Baseline, daily measurement until hospital discharge (avarage hospital stay: 10 days)
Daily measurement after initiation of plasma exchange therapy until treatment course is finished
次要结局
未报告次要终点
研究者
Julius Schmidt
MD
Hannover Medical School